Nitroxoline in Pediatric Patients: OEM Supplier & Manufacturer Insights

As a healthcare provider or a purchasing agent, you might be on the lookout for reliable solutions for your pediatric patients. Nitroxoline is an effective treatment that can be safely used in children, offering a powerful option for managing urinary infections. Our company works closely with top manufacturers to bring you high-quality Nitroxoline at competitive prices, I understand the importance of sourcing from trustworthy suppliers, and that’s why I want to highlight our commitment to quality and affordability. We aim to provide you with cheap yet effective options to support the health needs of young patients. Partnering with Shandong King's Land International Trading Co., Ltd guarantees that you will receive not just a product, but also dedicated support and reliability in your procurement process. Let’s work together to enhance the lives of pediatric patients with proven solutions like Nitroxoline!

Hot Selling Product

Nitroquinoline as an oral antibacterial drug for the treatment of urinary tract infections

8-Hydroxyquinazoline for metal ion extraction and metal ion determination

3,5-Dinitrosalicylic Acid: The Ultimate Reagent for Glucose Analysis

2-(4-Aminophenyl)ethanol for orgnic synthesis

4-Amino-m-cresol for Dye intermediate

6-nitro-m-creso for pharmaceutical intermediates-1

China Top Nitroxoline In Pediatric Patients Manufacturer Products

At our state-of-the-art production base strategically located in a leading chemical industrial park, we take pride in being a top manufacturer of Nitroxoline specifically tailored for pediatric patients. Our commitment to quality and excellence has positioned us as a trusted name in the global pharmaceutical market. With growing demand across regions including Russia, Europe, Africa, and Asia, our high-quality Nitroxoline has gained widespread acclaim among healthcare professionals and patients alike. Understanding the unique needs of pediatric care, we have developed our Nitroxoline products to ensure safety and efficacy in treating urinary tract infections in children. Our rigorous quality control measures and adherence to international standards ensure that every batch meets the highest specifications. As a responsible manufacturer, we are dedicated to producing medications that healthcare providers can confidently prescribe, knowing they are backed by reliable science and superior manufacturing practices. For global procurement professionals seeking reliable partners in the pharmaceutical industry, our commitment to quality, innovative production methods, and comprehensive customer support makes us the ideal choice. We invite you to explore our Nitroxoline offerings and experience the difference that comes from partnering with an esteemed manufacturer dedicated to advancing pediatric healthcare worldwide. Your trust in our products can help us together in delivering better health outcomes for children everywhere.

China Top Nitroxoline In Pediatric Patients Manufacturer Products

Product Name	Dosage Form	Dosage Strength	Indication	Manufacturer	Country
Nitroxoline Tablets	Tablet	100 mg	Urinary tract infections	Top Manufacturer	China
Nitroxoline Suspension	Oral Suspension	50 mg/5ml	Urinary tract infections	Leading Supplier	China
Nitroxoline Capsules	Capsule	200 mg	Urinary tract infections	Renowned Manufacturer	China
Nitroxoline Oral Drops	Oral Drops	25 mg/ml	Urinary tract infections	Trusted Supplier	China

Pediatric Nitroxoline Usage Trends in China (2020-2023)

The trend in the prescription of Nitroxoline among pediatric patients in China from 2020 to 2023 has shown a notable increase. The data illustrates a clear upward trajectory, starting from approximately 1,200 monthly prescriptions in 2020, peaking at around 2,200 in 2023. This increase could be attributed to growing awareness and indications for using Nitroxoline in treating pediatric urinary tract infections, combined with improved access to healthcare services. While there was a slight dip in 2022 to 1,600 prescriptions, the resurgence in 2023 indicates that healthcare providers are increasingly prescribing this medication as part of standard treatment protocols for young patients. The patterns observed in this chart can serve as an important reference for healthcare policymakers in evaluating drug utilization trends for pediatric care, assessing the need for further training among healthcare providers, and ensuring that effective treatments are readily available to children in need of care.